Overview

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Status:
RECRUITING

Trial end date:
2029-04-01

Target enrollment:

Participant gender:

Summary

To compare the efficacy and safety of tislelizumab combined with FOLFOX or combined with POF in the treatment of locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma with CPS1

Phase:

PHASE3

Details

Lead Sponsor:

Fujian Cancer Hospital

Treatments:

Fluorouracil
Levoleucovorin
Oxaliplatin
Paclitaxel
tislelizumab